Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-market, Confirmatory, Interventional, Randomized and Controlled Clinical Study to Assess the Efficacy and Safety of Sentinox in COVID-19 Patients.

NCT04909996 is registered in ClinicalTrials.gov with APR Applied Pharma Research s.a. as lead sponsor.

NCT NCT04909996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04909996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-market, Confirmatory, Interventional, Randomized and Controlled Clinical Study to Assess the Efficacy and Safety of Sentinox in COVID-19 Patients.
Lead sponsor
APR Applied Pharma Research s.a.
Phase
Not applicable
Overall status
Completed
Start date
May 20, 2021
Completion date
November 30, 2021
Enrollment
57 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 (sars-cov-2 infection)